Cibus (CBUS) Net Margin (2016 - 2026)

Cibus (CBUS) posted Net Margin of 3022.52% for Q4 2025, up 23.51% sequentially from 3951.71% in Q3 2025, and down 89347.0% YoY from N/an in Q4 2024.

Cibus (CBUS) Net Margin (2016 - 2026) Analysis & Trends

Cibus has reported Net Margin for 10 years, with the latest figure at 3022.52% in Q4 2025.

Quarterly Net Margin fell 89347.0% year-over-year to 3022.52% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 3632.89% (up 300045.0% YoY) and the FY2025 annual result came in at 3632.89%, up 300045.0% from the prior year.
Net Margin rose to 3022.52% in Q4 2025 per CBUS's latest filing, from 3951.71% in the prior quarter.
Over five years, Net Margin peaked at 40.46% in Q2 2021 and troughed at 25132.18% in Q4 2023.
A 5-year average of 6904.06% and a median of 4862.89% in 2024 frame the typical range for Net Margin.
The sharpest annual moves came in 2023 and 2024: Net Margin slumped 1837742 bps in 2023, then soared 2300314 bps in 2024.
Over 5 years, Net Margin stood at 363.2% in 2021, then tumbled by 1760 bps to 6754.76% in 2022, then slumped by 272 bps to 25132.18% in 2023, then jumped by 92 bps to 2129.04% in 2024, then sank by 42 bps to 3022.52% in 2025.
According to Business Quant data, Net Margin over the past three periods registered 3022.52%, 3951.71%, and 2846.52% for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	32.99%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	30.23%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	31.16%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-539.31%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	13.90%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	12.74%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-3.12%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	12.09%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-16.51%
10	Cibus	131.25 Mn	110.82 Mn	-	-2,227.87%

Download Data